Revance Therapeutics is a biotechnology company. Co. has two reportable segments: Product, which refers to the business that includes the research and development of aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection for various indications, the U.S. distribution of the RHA® Pipeline Products, and an onabotulinumtoxinA biosimilar in partnership with Viatris Inc.; and Service, which refers to the business of the HintMD platform, which is a registered payment facilitator and enables practices to process payments for their patients and provides subscription and pay-over-time solutions that support practices' aesthetic treatment plans. The RVNC stock yearly return is shown above.
The yearly return on the RVNC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RVNC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|